# A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

> **NCT05131997** · PHASE3 · COMPLETED · sponsor: **Addpharma Inc.** · enrollment: 290 (actual)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** AD-221
- **DRUG:** AD-221A
- **DRUG:** AD-221B
- **DRUG:** AD-221C

## Key facts

- **NCT ID:** NCT05131997
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2022-06-08
- **Final completion:** 2022-06-08
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05131997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05131997, "A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05131997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*